Rosen Comments on Proposed New FDA Guidance on Drug-Device Combination Products
December 5, 2017
Health Care on Bloomberg Law
Partner David Rosen is quoted in a Health Care on Bloomberg Law article, “FDA Seeks to Speed Approvals of Generic Drug-Device Combos,” about proposed new FDA guidance that will make it easier for generic companies to get drug-device combination products approved.
Rosen said the proposed guidance, which will allow a generic product to have certain labeling differences from the branded product if the labeling changes come from permitted design differences, could present safety issues.
“We have to make sure that there’s no potential for patient confusion, as well as caregiver confusion” if there are differences in the labeling, he said. “What we don’t want is something that is less safe or less effective than what is currently out there.”
Rosen said the proposed guidance, which will allow a generic product to have certain labeling differences from the branded product if the labeling changes come from permitted design differences, could present safety issues.
“We have to make sure that there’s no potential for patient confusion, as well as caregiver confusion” if there are differences in the labeling, he said. “What we don’t want is something that is less safe or less effective than what is currently out there.”
People
Related News
June 10, 2025
In the News
James McFall Joins Iconic Athletes and Leaders in Launch of Stanford Football Alumni United
Foley & Lardner LLP is proud to announce that partner James Carlos McFall is a founding member of Stanford Football Alumni United (SFAU), a newly formed coalition of former players and leaders committed to supporting Stanford Football’s continued growth and national competitiveness.
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."
June 6, 2025
In the News
Louis Lehot Comments on Crypto Company IPO – 'Definitely a home run'
Foley & Lardner LLP partner Louis Lehot commented on the initial public offering of stablecoin issuer Circle in the Law360 article, "Circle's Smash IPO Could Pave Way For More Crypto Listings."